My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0464
    CAS #: 1234480-50-2Purity ≥98%

    Description: XMD8-92 (XMD-8-92) is a novel, potent and highly selective dual inhibitor of BMK1/ERK5 (big mitogen activated protein kinase 1 / extracellular-signal-regulated kinase) with potential antineoplastic activity. It inhibits BMK1/ERK5 with a Kd of 80 nM, and shows less potency against DCAMKL2, TNK1, and Plk4 (Kds of 190, 890, and 600 nM, respectively). It shows potent anti-proliferative activity in vitro and high in vivo antitumor efficacy in a pancreatic tumor xenograft model via a DCLK1-dependent mechanism. ERK5 pathway regulates transcription factors important for monocytic differentiation of human myeloid leukemia cells. The big mitogen activated protein kinase 1 (BMK1) pathway is the most recently discovered and least-studied mammalian mitogen-activated protein (MAP) kinase cascade, ubiquitously expressed in all types of cancer cells tested so far. Mitogens and oncogenic signals strongly activate this cellular MAP kinase pathway, thereby passing down proliferative, survival, chemoresistance, invasive, and angiogenic signals in tumor cells.

    References: Cancer Cell. 2010 Sep 14;18(3):258-67; Cancer Lett. 2014 Aug 28;351(1):151-61. 

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)474.55
    CAS No.1234480-50-2
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 73 mg/mL (153.8 mM)
    Water: <1 mg/mL
    Ethanol: <1 mg/mL
    Other infoChemical Name: 2-[[2-ethoxy-4-(4-hydroxy-1-piperidinyl)phenyl]amino]-5,11-dihydro-5,11-dimethyl-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one
    InChi Code: InChI=1S/C26H30N6O3/c1-4-35-23-15-17(32-13-11-18(33)12-14-32)9-10-20(23)28-26-27-16-22-24(29-26)30(2)21-8-6-5-7-19(21)25(34)31(22)3/h5-10,15-16,18,33H,4,11-14H2,1-3H3,(H,27,28,29)
    SynonymsXMD 8-92; XMD892; XMD-892; XMD8-92; XMD-8-92; XMD 892

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity: XMD8-92, via inhibition of BMK1 activation, significantly induces p21 expression in cells, and mediates suppression of cancer cell proliferation. XMD8-92 markedly abrogates the inhibitive effects of hydroxysafflor yellow A (HSYA) on hepatic stellate cell (HSC) activation, and blockes the HSYA-mediated MEF2C down-regulation.

    Kinase Assay: KiNativ profiling of XMD8-92 is carried out with both an ATP and ADP acylphosphate-desthiobiotin with the following modifications. HeLa cell lysates (5 mg/mL total protein) are incubated in the presence of XMD8-92 at 50 μM, 10 μM, 2 μM, 0.8 μM, and 0 μM for 15 minutes prior to addition of the ATP or ADP acylphosphate probe (5 μM final probe concentration). All reactions are performed in duplicate. Probe reactions proceeded for 10 minutes and the reaction stopped by the addition of urea and processed for MS analysis. Samples are analyzed by LC-MS/MS on a linear ion trap mass spectrometer using a time segmented “target list” designed to collect MS/MS spectra from all kinase peptide-probe conjugates that can be detected in HeLa cell lysates. This target list is generated and validated by prior exhaustive analysis of HeLa lysates. Up to four characteristic fragment ions for each kinase peptide-probe conjugate are used to extract signals for each kinase, and a comparison of inhibitor treated to control (untreated) lysates allow for precise determination of % inhibition at each point. A manuscript describing the details of this targeted mass spectrometry approach is in preparation.

    In VivoXMD8-92 (50 mg/kg i.p.) significantly inhibit the growth of the xenografted human or syngeneic mouse tumors by blocking tumor cell proliferation and tumor-associated angiogenesis. XMD8-92 inhibits pancreatic tumor xenograft growth by significant downregulation of DCLK1 and several of its downstream targets
    Animal modelmouse
    Formulation & Dosage50 mg/kg; i.p.
    ReferencesCancer Cell. 2010 Sep 14;18(3):258-67; Cancer Lett. 2014 Aug 28;351(1):151-61. 

    These protocols are for reference only. InvivoChem does not independently validate these methods.


    Antitumor efficacy of XMD8-92. (A) A549 cells were injected subcutaneously into the flanks of Nod/Scid mice. (B) Mouse xenograft models were established as described in Experimental Procedures. (C) Fluorescence microscopy images of HeLa or LL/2 tumor sections from XMD8-92 treated or control mice as indicated.   2010 Sep 14;18(3):258-67.


    Development of a Pharmacological Inhibitor of BMK1. (A) Chemical structure of XMD8-92.
    (B) HeLa cells were serum starved overnight followed by treatment with 1 or 5 μM XMD8-92 or 1 μM PD184352 as indicated for one hour. (C) HEK293 cells were co-transfected with expression plasmids of MEK5D and BMK1.  2010 Sep 14;18(3):258-67.


    Activated BMK1 Translocates from the Cytosol to Colocalize with PML in the Nucleus.


    BMK1 is in Complex with PML and Suppresses the Anti-Cancer Function of PML in Tumor Cells.  2010 Sep 14;18(3):258-67.


    BMK1 Regulates PML Function through Phosphorylation.  2010 Sep 14;18(3):258-67.


    Pharmacological inhibition of BMK1 suppresses tumor growth through PML.  2010 Sep 14;18(3):258-67.


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?